文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肠外表现可能会增加克罗恩病患者发生其他肠外表现同步和异时发展的风险。

Extra intestinal manifestations may increase the risk of synchronous and metachronous development of other extraintestinal manifestations in patients with Crohn's disease.

作者信息

Ozkahraman Adnan, Kayar Yusuf, Dertli Ramazan, Konur Sevki, Kılıc Guner, Baran Bulent, Ormeci Asli Cifcibasi, Akyuz Filiz, Demir Kadir, Besisik Fatih, Kaymakoglu Sabahattin

机构信息

Department of Internal Medicine, Van Teaching and Research Hospital, Health Sciences University, Van, Turkey.

Division of Gastroenterology, Department of Internal Medicine, Van Teaching and Research Hospital, Health Sciences University, Van, Turkey.

出版信息

Sci Rep. 2025 Jul 1;15(1):20629. doi: 10.1038/s41598-025-07180-6.


DOI:10.1038/s41598-025-07180-6
PMID:40594471
Abstract

Although Crohn's disease (CD) affects the intestines, it is known to be a systemic disease rather than being limited to the intestines. Extra intestinal manifestations (EIMs) accompanying CD are reported at rates varying from 6 to 53%. While EIM negatively affects the quality of life of some patients, some EIMs, such as primary sclerosing cholangitis and thromboembolism, can be life-threatening. Although more than one EIM can occur simultaneously, the development of one EIM increases the probability of developing another EIM. There are few studies on how EIMs affect each other. The aim of this study was to examine the frequency of EIMs accompanying CD and their interactions with each other. This study included patients with CD who were under regular follow-up from March 1986 to October 2011. Accompanying EIMs and the time of development were recorded. The frequency of EIMs and their associations with each other were investigated. In total, 336 patients with CD (55.4% male) with a mean follow-up duration of 7.54 years (range, 6 months-25.4 years) were evaluated. At the time of CD diagnosis, 21.1% of the patients had at least one EIM, and at the end of the 25-year follow-up period, the prevalence of EIMs was 47.3%. The prevalence of multiple EIMs was 12.2% and 22.9% at the onset of CD and at the 25-year follow-up, respectively. Oral, joint 9.2%, respectively) were the most common EIMs. The development and skin involvement (32.4%, 24.7%, and of peripheral arthritis was significantly associated with axial spondiloarthropathy, skin involvement, ocular involvement, oral ulcers, and vascular thromboembolism (p < 0.05). There was a significant relationship between oral ulcers and peripheral arthritis, axial arthritis, skin involvement, ocular involvement, liver involvement and thromboembolism (p < 0.05). No significant relationship was detected between neurological involvement and any other EIMs. The development of EIMs in patients with CD may trigger the development of other EIMs during the course of the disease.

摘要

虽然克罗恩病(CD)累及肠道,但它是一种全身性疾病,而非局限于肠道。据报道,CD伴发的肠外表现(EIMs)发生率在6%至53%之间。虽然EIMs对部分患者的生活质量有负面影响,但一些EIMs,如原发性硬化性胆管炎和血栓栓塞,可能危及生命。虽然多种EIMs可能同时出现,但一种EIM的发生会增加出现另一种EIM的可能性。关于EIMs如何相互影响的研究较少。本研究的目的是调查CD伴发EIMs的频率及其相互作用。本研究纳入了1986年3月至2011年10月期间接受定期随访的CD患者。记录伴发的EIMs及其发生时间。调查EIMs的频率及其相互关联。共评估了336例CD患者(男性占55.4%),平均随访时间为7.54年(范围为6个月至25.4年)。在CD诊断时,21.1%的患者至少有一种EIMs,在25年随访期结束时,EIMs的患病率为47.3%。在CD发病时和25年随访时,多种EIMs的患病率分别为12.2%和22.9%。口腔、关节和皮肤受累(分别为32.4%、24.7%和9.2%)是最常见的EIMs。外周关节炎的发生与中轴型脊柱关节炎、皮肤受累、眼部受累、口腔溃疡和血管血栓栓塞显著相关(p<0.05)。口腔溃疡与外周关节炎、中轴关节炎、皮肤受累、眼部受累、肝脏受累和血栓栓塞之间存在显著关系(p<0.05)。未发现神经受累与任何其他EIMs之间存在显著关系。CD患者中EIMs的发生可能在疾病过程中引发其他EIMs的发生。

相似文献

[1]
Extra intestinal manifestations may increase the risk of synchronous and metachronous development of other extraintestinal manifestations in patients with Crohn's disease.

Sci Rep. 2025-7-1

[2]
Vitamin D for the treatment of inflammatory bowel disease.

Cochrane Database Syst Rev. 2023-10-2

[3]
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.

Cochrane Database Syst Rev. 2021-11-29

[4]
A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Health Technol Assess. 2011-2

[5]
Home treatment for mental health problems: a systematic review.

Health Technol Assess. 2001

[6]
Ocular Manifestations of Paediatric Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

J Crohns Colitis. 2018-6-28

[7]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[8]
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.

Syst Rev. 2024-11-26

[9]
Systemic and topical antibiotics for chronic rhinosinusitis.

Cochrane Database Syst Rev. 2016-4-26

[10]
Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD).

Cochrane Database Syst Rev. 2023-10-9

本文引用的文献

[1]
Risk factors associated with progression to intestinal complications of Crohn disease.

Chin Med J (Engl). 2019-10-20

[2]
Clinical outcomes and risk factors of secondary extraintestinal manifestation in ulcerative colitis: results of a multicenter and long-term follow-up retrospective study.

PeerJ. 2019-6-21

[3]
The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults.

Transl Pediatr. 2019-1

[4]
Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis.

Expert Rev Gastroenterol Hepatol. 2019-2-20

[5]
Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients.

PLoS One. 2018-7-10

[6]
Skin Manifestations of Inflammatory Bowel Disease.

Clin Rev Allergy Immunol. 2017-12

[7]
Microbiome-Linked Crosstalk in the Gastrointestinal Exposome towards Host Health and Disease.

Pediatr Gastroenterol Hepatol Nutr. 2016-12

[8]
The safety of vedolizumab for ulcerative colitis and Crohn's disease.

Gut. 2017-5

[9]
Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease.

J Crohns Colitis. 2016-4

[10]
The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease.

J Crohns Colitis. 2016-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索